文献速递胸部肿瘤消化系统肿瘤泌尿男性生殖肿瘤

NCI-MATCH基因组引导试验的分子 landscape 与可操作变异

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
PubMed 文献 · J Clin Oncol · 2020-10-13

NCI-MATCH是一项主筛选协议,对5954例难治性肿瘤患者的活检标本进行集中NGS检测,并将携带可操作分子变异者分配至30个平行单臂II期子方案。93.0%标本检测成功,37.6%发现可操作变异,最终17.8%被分配治疗。可操作性率因组织学类型而异,共同耐药突变常见,支持联合靶向治疗研究。

要点

  • NCI-MATCH对5954例难治性肿瘤集中NGS检测,93.0%成功,37.6%发现可操作变异。
  • 经临床和分子排除标准后,17.8%患者被分配至治疗子方案。
  • 可操作性率因组织学而异,尿路上皮癌>35%,胰腺癌和小细胞肺癌<6%。

核心结论

  • 在多个 accrual 站点的大型复杂试验中,对大量患者进行分子筛选以测试针对中等频率分子靶点的研究性治疗是可行的。
  • 共同存在的耐药突变常见,支持研究联合靶向治疗方案。

研究设计与样本

  • 主筛选协议对来自1117个 accrual 站点的5954例难治性恶性肿瘤患者的肿瘤活检标本进行集中下一代测序(NGS)和选定免疫组化分析。
  • 携带由靶向治疗针对的肿瘤分子变异且该治疗在该肿瘤类型缺乏既定疗效的患者,被分配至30个平行、单臂、II期子方案之一。

主要发现

  • 分子谱分析在93.0%的标本中成功。
  • 37.6%的标本中发现可操作变异。
  • 应用临床和分子排除标准后,17.8%被分配(若所有子方案同时可用,26.4%可被分配)。
  • 截至本报告,11个子方案达到 accrual 目标。
  • 可操作性率因组织学而异(例如,尿路上皮癌>35%,胰腺癌和小细胞肺癌<6%)。

临床怎么用

  • 对于难治性恶性肿瘤患者,可考虑集中NGS检测以识别可操作分子变异并匹配靶向治疗临床试验。
  • 可操作性率因肿瘤组织学类型差异较大,尿路上皮癌较高而胰腺癌和小细胞肺癌较低。
  • 共同耐药突变常见,提示联合靶向治疗策略可能值得探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy specimens were analyzed centrally with next-generation sequencing (NGS) in a master screening protocol. Patients with a tumor molecular alteration addressed by a targeted treatment lacking established efficacy in that tumor type were assigned to 1 of 30 treatments in parallel, single-arm, phase II subprotocols. PATIENTS AND METHODS: Tumor biopsy specimens from 5,954 patients with refractory malignancies at 1,117 accrual sites were analyzed centrally with NGS and selected immunohistochemistry in a master screening protocol. The treatment-assignment rate to treatment arms was assessed. Molecular alterations in seven tumors profiled in both NCI-MATCH trial and The Cancer Genome Atlas (TCGA) of primary tumors were compared. RESULTS: Molecular profiling was successful in 93.0% of specimens. An actionable alteration was found in 37.6%. After applying clinical and molecular exclusion criteria, 17.8% were assigned (26.4% could have been assigned if all subprotocols were available simultaneously). Eleven subprotocols reached their accrual goal as of this report. Actionability rates differed among histologies (eg, > 35% for urothelial cancers and < 6% for pancreatic and small-cell lung cancer). Multiple actionable or resistance-conferring tumor mutations were seen in 11.9% and 71.3% of specimens, respectively. Known resistance mutations to targeted therapies were numerically more frequent in NCI-MATCH than TCGA tumors, but not markedly so. CONCLUSION: We demonstrated feasibility of screening large numbers of patients at numerous accruing sites in a complex trial to test investigational therapies for moderately frequent molecular targets. Co-occurring resistance mutations were common and endorse investigation of combination targeted-therapy regimens.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020. PMID: 33048619. doi:10.1200/JCO.19.03010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。